Bibliographic record
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised…
Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T. The Lancet 2023
§1Bibliographic record
§1.1Record
- Authors
- Rosenstock J, Frias J, Jastreboff AM, Du Y, Lou J, Gurbuz S, Thomas MK, Hartman ML, Haupt A, Milicevic Z, Coskun T
- Title
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo- and active-controlled, parallel-group, phase 2 trial
- Source
- The Lancet
- Year
- 2023
- Volume, issue, pages
- 402(10401):529–544
- Digital object identifier
- 10.1016/S0140-6736(23)01053-X
- PubMed identifier
- 37385280
- Record type
- Journal article
- Institute identifier
- CEI-BR-093
§1.2Institute documents citing this record
Table 1. Documents in the Institute set that cite this record.
| Document | Series |
|---|---|
| Monograph: Retatrutide | Compound monograph |
| Synthesis: Retatrutide in obesity and overweight in adults: effect on the anchor… | Evidence synthesis |
| Synthesis: Retatrutide in type 2 diabetes mellitus: effect on the anchor outcome | Evidence synthesis |
| Synthesis: Retatrutide in obesity and overweight in adults: tolerability and… | Evidence synthesis |
| Synthesis: Retatrutide in type 2 diabetes mellitus: tolerability and… | Evidence synthesis |
| Synthesis: Retatrutide in obesity and overweight in adults: durability of effect | Evidence synthesis |
| 6 citing documents. | |
§1.3Subject tags
retatrutide t2dm TRIUMPH
Compound Evidence Institute · CEI-BR-093 · https://compoundevidence.com/bibliography/rosenstock2023/ · retrieved 30 July 2026